Core Viewpoint - Yifan Pharmaceutical stated that according to current accounting standards, recognized impairment of intangible assets cannot be reversed, but the company will continue to strive to further explore the market value of the product [2] Group 1 - Yifan Pharmaceutical has acknowledged the impairment of intangible assets and clarified that it cannot be reversed under existing accounting regulations [2] - The company is committed to enhancing the market value of its products despite the impairment [2]

Group 1 - The core point of the article is that Yifan Pharmaceutical (002019) reported a total of 48,356 shareholders as of January 20, 2026 [1]

Core Viewpoint - The company YiFan Pharmaceutical (002019.SZ) has received approval from the Health Sciences Authority (HSA) of Singapore for the market registration of its chemical drug, racemic norepinephrine injection solution, which is intended for the treatment of severe acute hypotension in adults [1] Group 1 - The company's subsidiary, SciGen Pte. Ltd., is responsible for the newly approved product [1] - The approved product is specifically designed to control blood pressure levels in adults experiencing severe acute hypotension [1]

Core Viewpoint - Yifan Pharmaceutical's product Yilishu is still in the early stages of market introduction in the United States, with sales volume dependent on procurement agreements and actual orders rather than terminal sales [2] Group 1 - Yifan Pharmaceutical responded to investor inquiries on February 6, indicating that the procurement volume of Yilishu's U.S. partner is based on agreements and orders [2] - The product has been on the U.S. market for less than a year and is currently in the initial ramp-up phase [2]

Core Viewpoint - The company YiFan Pharmaceutical (002019.SZ) has received approval from the Health Sciences Authority (HSA) of Singapore for the market registration of its chemical drug, racemic norepinephrine injection solution, which is intended for the treatment of severe acute hypotension in adults [1] Group 1 - YiFan Pharmaceutical's wholly-owned subsidiary, SciGen Pte. Ltd., has been granted a market registration approval by HSA [1] - The approved product, racemic norepinephrine injection solution, is used for blood pressure control in adults experiencing severe acute hypotension [1] - The drug is designed to elevate blood pressure levels in critical situations [1]

证券代码：002019 证券简称：亿帆医药 公告编号：2026-010 亿帆医药股份有限公司 关于重酒石酸去甲肾上腺素注射用浓溶液获得新加坡注册 批文的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 亿帆医药股份有限公司（以下简称"公司"）全资子公司SciGen Pte. Ltd.于 近日收到新加坡卫生科学局（Health Sciences Authority）（以下简称"HSA"） 核准签发的上市注册批文，批准公司化药产品重酒石酸去甲肾上腺素注射用浓溶 液在新加坡上市销售。现将相关情况公告如下： 一、药品注册主要信息 的子公司生产线通过新加坡PIC/S GMP认证，标志着公司质量管理体系和生产能 力再次得到国际权威认证机构的认可，为公司境内化药注射剂产品拓展国际市场 提供了坚实保障。 3、剂型：注射剂 4、规格：4mg/4mL 5、生产厂家：合肥亿帆生物制药有限公司 6、注册编号：SIN17453P 二、产品简介 重酒石酸去甲肾上腺素注射用浓溶液适用于成人严重、急性低血压状态的血 压控制（可提升血压水平）。2023年3月，该产品在国内获批上市。公司于2 ...

Core Viewpoint - The company, Yifan Pharmaceutical, is in the early stages of market introduction for its product, Yilishu, in the U.S. and is not yet experiencing significant sales volume [1] Group 1 - The procurement volume of Yilishu by its U.S. partner is determined by agreements and orders, which may not directly correlate with actual end-user sales [1] - Yilishu has been on the U.S. market for less than a year and is still in the initial ramp-up phase of its introduction [1]

Investment Rating - The industry rating is neutral, indicating that the overall return is expected to be between -5% and 5% relative to the CSI 300 index over the next six months [9]. Core Insights - The pharmaceutical sector experienced a decline of 2.42% on February 2, 2025, underperforming the CSI 300 index by 0.29 percentage points, ranking 16th among 31 sub-industries [4]. - Key performers in the sector included hospitals (-0.99%), pharmaceutical distribution (-1.63%), and blood products (-1.65%), while other biopharmaceuticals (-3.69%) and offline pharmacies (-3.09%) lagged behind [4]. - Elevar has submitted a New Drug Application (NDA) to the FDA for Lirafugratinib, a selective oral FGFR2 inhibitor, showing a 46.5% objective response rate (ORR) in clinical trials for cholangiocarcinoma patients [5]. - The disease control rate for Lirafugratinib reached 96.5%, with a median progression-free survival (PFS) of 11.3 months and a median overall survival (OS) of 22.8 months [5]. - Jichuan Pharmaceutical has signed an exclusive commercialization agreement for a nasal spray in Greater China, with a payment of up to 100 million RMB [5]. - Heng Rui Pharmaceutical received FDA acceptance for its BLA submission for a combination therapy for liver cancer [6]. - Shanghai Yizhong reported a projected revenue of 317 million RMB for 2025, reflecting an 82.72% year-on-year growth [6]. Sub-industry Ratings - Chemical pharmaceuticals: No rating - Traditional Chinese medicine: No rating - Biopharmaceuticals II: Neutral - Other pharmaceuticals: Neutral [3].

Core Viewpoint - The company has approved a comprehensive credit financing limit of up to RMB 650 million and a guarantee limit of up to RMB 600 million for itself and its subsidiaries, aimed at supporting business operations and development [2][5]. Group 1: Guarantee Adjustment Situation - The company has adjusted the unused guarantee limits of its subsidiaries, transferring a total of RMB 16 million to its wholly-owned subsidiary Hefei Yifan Pharmaceutical Co., Ltd. (合肥亿帆) [3]. - After the adjustment, the guarantee limits for Sichuan Defeng Pharmaceutical Co., Ltd., Anqing Xinfuhua Chemical Co., Ltd., and Xinfuhua Technology Co., Ltd. have been reduced to zero, while the limit for Hefei Yifan has increased from RMB 88 million to RMB 104 million [3]. Group 2: Guarantee Overview - The company signed an irrevocable maximum guarantee agreement with China Merchants Bank Hefei Branch, agreeing to provide a joint liability guarantee for Hefei Yifan's debts, with a maximum guarantee amount of RMB 10 million [4]. - The guarantee is valid for the duration of the loans or financing agreements under the credit agreement, extending three years beyond the maturity of each loan [9]. Group 3: Financial and Operational Context - Hefei Yifan, established on September 9, 2022, is a wholly-owned subsidiary of the company, with a registered capital of RMB 100 million and involved in various pharmaceutical and medical-related activities [6][7]. - The company has confirmed that Hefei Yifan is not a dishonest executor and has the capability to repay its debts [10]. Group 4: Cumulative Guarantee Situation - As of the report date, the total external guarantee balance of the company and its subsidiaries is RMB 5.132 billion, accounting for 60.22% of the company's audited net assets for 2024 [11].

Group 1 - The company has approved a total credit limit of up to RMB 650 million and a guarantee limit of up to RMB 600 million for itself and its subsidiaries [2][5] - The company has reallocated unused guarantee limits from subsidiaries to its wholly-owned subsidiary Hefei Yifan Pharmaceutical Co., increasing its guarantee limit from RMB 88 million to RMB 104 million [3] - As of the announcement date, the remaining guarantee balance for Hefei Yifan is RMB 93.6 million [3] Group 2 - The company signed an irrevocable maximum guarantee agreement with China Merchants Bank Hefei Branch, agreeing to provide a joint liability guarantee for Hefei Yifan's debts, with a maximum guarantee amount of RMB 10 million [4][7] - The guarantee covers loans and other credit balances within the approved credit limit, including related interest and fees [8] - The guarantee period extends until the expiration of each loan or financing agreement plus an additional three years [8] Group 3 - Hefei Yifan is a wholly-owned subsidiary of the company, established on September 9, 2022, with a registered capital of RMB 100 million [6] - The subsidiary is not listed as a dishonest executor and has stable operations, indicating its ability to repay debts [9][10] - The cumulative external guarantee balance after this new guarantee is RMB 5.132 billion, accounting for 60.22% of the company's audited net assets for 2024 [10]